Mostrar el registro sencillo del ítem
A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19)
dc.contributor.author | Chen, Jun | |
dc.date.accessioned | 2020-03-25T12:53:51Z | |
dc.date.available | 2020-03-25T12:53:51Z | |
dc.date.issued | 2020-03-06 | |
dc.identifier.uri | http://www.zjujournals.com/med/EN/10.3785/j.issn.1008-9292.2020.03.03 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/806 | |
dc.description.abstract | Objective: To evaluate the efficacy and safety of hydroxychloroquine (HCQ) in the treatment of patients with common coronavirus disease-19 (COVID-19). Methods: We prospectively enrolled 30 treatment-na?ve patients with confirmed COVID-19 after informed consent at Shanghai Public Health Clinical Center. The patients were randomized 1:1 to HCQ group and the control group. Patients in HCQ group were given HCQ 400 mg per day for 5 days plus conventional treatments, while those in the control group were given conventional treatment only. The primary endpoint was negative conversion rate of COVID-19 nucleic acid in respiratory pharyngeal swab on days 7 after randomization. This study has been approved by the ethics committee of Shanghai public health clinical center and registered online (NCT04261517). Results: One patient in HCQ group developed to severe during the treatment. On day 7, COVID-19 nucleic acid of throat swabs was negative in 13 (86.7%) cases in the HCQ group and 14 (93.3%) cases in the control group (P>0.05). The median duration from hospitalization to virus nucleic acid negative conservation was 4 (1-9) days in HCQ group, which is comparable to that in the control group[2 (1-4) days, (U=83.5, P>0.05)]. The median time for body temperature normalization in HCQ group was 1 (0-2) after hospitalization, which was also comparable to that in the control group 1 (0-3). Radiological progression was shown on CT images in 5 cases (33.3%) of the HCQ group and 7 cases (46.7%) of the control group, and all patients showed improvement in follow-up examination. Four cases (26.7%) of the HCQ group and 3 cases (20%) of the control group had transient diarrhea and abnormal liver function (P>0.05). Conclusions: The prognosis of common COVID-19 patients is good. Larger sample size study are needed to investigate the effects of HCQ in the treatment of COVID-19. Subsequent research should determine better endpoint and fully consider the feasibility of experiments such as sample size. | en_US |
dc.language | English | en_US |
dc.subject | Hydroxychloroquine | en_US |
dc.title | A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19) | en_US |
eihealth.country | China | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Artículo publicado | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | J Zhejiang Univ (Med Sci) | en_US |
Ficheros en el ítem
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |